Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanogen asset sale to Elitech subject to court approval

This article was originally published in The Gray Sheet

Executive Summary

Delaware bankruptcy court will review molecular and rapid diagnostic product maker Nanogen's recent chapter 11 filing and a proposed sale of the firm's assets to private French diagnostics firm Elitech for $25.7 million, Nanogen announces May 14. The asset sale will be subject to a court-supervised auction in which interested parties may submit better offers. Nanogen and Elitech initially had planned a stock-swap merger, but San Diego-based Nanogen was unable to secure working capital (1"The Gray Sheet" Feb. 2, 2009, In Brief)

Related Content

Nanogen weighs alternatives to Elitech merger





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts